Tanespimycin
17-烯丙氨基格尔德霉素
Report date: 2024/07/05 11:15:12
NME
Base Information
Drug NameTanespimycin
Drug Alias Name +[12]
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[72]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[4]
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesNational Cancer InstituteBristol-Myers Squibb Company
China Registration ClassClass 1 Chemical Drug in China
Develop Information
Active CompaniesN/A
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)Bristol Myers Squibb SrlcompanyBiogen Inc +[6]
Active IndicationsN/A
Inactive Indications +[72]